Part 3: Chimeric vaccines combine strengths of each antigen to provide better coverage
What is “cell-mediated immunity” and how does it affect vaccine performance? Are two PCV2 genotypes necessarily better than one? And what does a monster from Greek mythology have to do with building a better vaccine?
In an interview with Pig Health Today, veterinary immunologist Meggan Bandrick, DVM, PhD, popped the hood on the US pork industry’s newest PCV2 vaccine and answered these questions in practical terms.
Watch the full interview or each part separately:
Posted on November 28, 2018